How to reduce labeling errors and prevent recalls in regulated industries

Even at the FDA’s benchmark for careful human proofreading — 97 to 98% accuracy — a standard 2,600-word patient leaflet still has roughly 52 words that could be wrong. That’s not a knock on any individual reviewer. It’s what happens when the last line of defense for a safety-critical document is a person reading it closely enough, one more time, to catch something that shouldn’t be there anymore.

The numbers on where that gap leads are stark: more than half of product recalls in life sciences trace back to packaging and labeling content, not manufacturing failures. A typical recall costs a minimum of US$1 million once you count product recovery, repackaging, regulatory remediation, and the corrective action that follows — and complex cases run past US$100 million. Sometimes the cost shows up before a recall even happens: one manufacturer caught a labeling misprint just before a seasonal product launch, and the resulting delay alone cost hundreds of millions in lost market share. We go deeper on that math in our look at the hidden cost of getting content verification wrong — this piece focuses on the practical side: what actually reduces the error rate, and what role automated proofreading plays in that.

Key takeaways

• More than 50% of life sciences recalls come from labeling and packaging content, not manufacturing defects — and even a near-miss caught late can cost more than the recall itself.
• The most reliable fixes are process fixes: standardized source content, real version control, separating drafting from verification, and an audit trail on every change.
• Automated proofreading doesn’t replace human review — it removes the risk of missing something in it, catching deviations a read-through consistently misses.
• Most labeling errors fall into a short list of repeatable patterns (dropped words, decimal shifts, outdated versions, translation drift) — each one maps to a specific way of catching it before print.

What are the best ways to reduce labeling errors in regulated industries?

The most effective fixes aren’t clever — they’re structural, and they hold regardless of whether you’re in pharma, medical device, or FMCG:

• Standardize your source content. Every version of a label should start from the same approved template and approved wording, not get re-typed or re-formatted from scratch each time.
• Build in real version control. The single most common root cause behind a labeling recall isn’t a typo — it’s an outdated or unapproved version making it into production because nothing flagged that it wasn’t the current one.
• Separate drafting from verification. The person or system checking a label shouldn’t be the same one who wrote it. A second, independent check is what catches what the original author’s eye slides right past.
• Add a deterministic compare step before sign-off. A read-through, however careful, is a sampling exercise. A version-to-version comparison isn’t — it checks the whole document, every time.
• Keep a full audit trail. Every change should be traceable to a person, a reason, and an approval, so “what changed and why” is never a reconstruction exercise after the fact.

Our regulatory guidelines for labeling in pharma piece covers the compliance backdrop these practices sit inside, and why labeling is critical for compliance, safety, and risk prevention makes the broader case for why this list matters as much as it does.

How can automated proofreading help prevent recalls due to labeling mistakes?

Automated proofreading checks a label, artwork file, or leaflet against the last approved version — in any language, across file formats — and flags every difference for a human to review, rather than asking a human to find the differences themselves.

That distinction matters more than it sounds. Manual proofreading, used as the primary check, typically runs 3–4 correction cycles per submission, with each cycle pulling in multiple stakeholders and compressing the timeline further. A multilingual instructions-for-use document running to roughly 250,000 words can take a professional reviewer several days to get through in a single language, with no guarantee every deviation surfaced. Automated comparison turns a review that takes a person 3–4 hours into a matter of minutes, and reviewers spend that time working through flagged deviations instead of re-reading an entire document top to bottom. See what automated proofreading actually involves for the mechanics, and — since not every tool billed as “proofreading software” does this the same way — what most proofreading software gets wrong about compliance is worth reading before assuming any comparison tool clears the bar a regulated review needs.

One caveat worth stating plainly: automated proofreading reduces the risk of the errors that most often lead to recalls. It’s risk reduction, not a guarantee — regulated labeling still needs a human to review and approve. The two work together; one doesn’t replace the other.

The real cost of a labeling error

The costs split into two buckets, and the second one is easy to underweight.

Direct costs are the obvious ones: recall logistics, destroyed stock, re-labeling and re-approval cycles, and — if the FDA judges a company’s corrective action inadequate — escalating consequences including warning letters and intensified scrutiny on top of the original incident.

Indirect costs are less visible but often larger: regulatory scrutiny on future submissions, strained distributor and buyer trust, and lost time-to-market. That last one doesn’t require an actual recall to bite — a labeling misprint caught just before a seasonal launch can push a product past its window entirely, with the resulting loss of market share dwarfing what the recall itself would have cost. Full breakdown, including how those numbers get modeled, is in the hidden cost of getting it wrong.

The real examples are the most persuasive part of this argument, and there’s no shortage of them. A pharmaceutical leaflet once stated a drug “should be taken during breastfeeding” instead of “should not be taken” — one missing word. Fifty-six lots of an asthma treatment were recalled in the US because the carton label omitted required information about when to stop treatment and consult a doctor. A missing dash turned “take 1-2 tablets a day” into “take 12 tablets a day” — a Class I recall risk, given the overdose danger. “Store at 1-4°C” became “Store at 14°C,” enough to compromise a product’s efficacy. Every one of these is documented in common labeling errors that lead to pharmaceutical recalls.

Medical device labeling carries the same risk profile. Roughly 10% of medical device recalls over the years trace back to non-compliant labeling rather than a manufacturing or design fault — including a 2023 FDA recall of Teleflex and Arrow International catheter kits after packaging listed a chlorhexidine-coated product as non-coated. Ensuring patient safety: the medical device recall process and prevention strategies walks through that case and what a recall-prevention strategy needs to cover.

Building an error-prevention workflow, not just a proofreading step

Treat prevention as a process, not a single checkpoint: draft, automated verification, human review, approval, archive — with an audit trail generated at every stage rather than reconstructed after the fact if a regulator asks. Risk 5 in our look at 2026’s top regulatory compliance risks covers exactly this tension between speed and accuracy, and why cutting corners in manual review tends to catch up with teams under launch-timeline pressure.

TVT Workflow shows how text, artwork, and barcode verification connect end to end rather than living as separate checks bolted onto different stages — which is where most of the review-cycle time actually gets recovered.